Corticosteroids for treating sepsis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Annane, Djillali ^a   Bellissant, Eric ^b   Bollaert, Pierre Edouard ^c   Briegel, Josef ^d   Keh, Didier ^e   Kupfer, Yizhak ^f  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOSE; SODIUM CHLORIDE; DEXAMETHASONE; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE;

ALL CAUSE MORTALITY; CLINICAL OUTCOME; DEATH; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; HEALTH CARE; HOSPITAL MORTALITY; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY RATE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR WEAKNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SUPERINFECTION; SUPPORTIVE TREATMENT; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT DURATION; WEAKNESS; ADULT; CHILD; INTENSIVE CARE; META ANALYSIS; MORTALITY; ORGAN DYSFUNCTION SCORE; SHOCK, SEPTIC; TIME FACTOR;

ADRENAL CORTEX HORMONES; ADULT; CHILD; CRITICAL CARE; DEXAMETHASONE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; METHYLPREDNISOLONE; ORGAN DYSFUNCTION SCORES; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC; TIME FACTORS;

EID: 84965191167     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002243.pub3     Document Type: Review

References (127)

1. Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71. [PUBMED: 12186604]
2. COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010;303:341-8.
3. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. Canadian Medical Association Journal 2011;182:1971-7.
4. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Critical Care Medicine 1998;26(4):645-50. [PUBMED: 9559600]
5. Bone RG, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 1987;317(11):653-8.
6. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine 1999;27(4):723-32. [PUBMED: 10321661]
7. Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock. Critical Care Medicine 1999;27(1):A33.
8. Cicarelli DD, Vieira JE, Benseñor FE. Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Medical Journal 2007;125:237-41. [PUBMED: 17992396]
9. Confalonieri M, Urbino R, Potena A, Piatella M, Parigi P, Giacomo P, et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine 2005;171:242-8.
10. Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:462-5.
11. Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 2014;42:1325-33.
12. Hu B, Li JG, Liang H, Zhou Q, Yu Z, Li L, et al. The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21:529-31.
13. Huh JW, Lim CM, Koh Y, Hong SB. Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine 2007;34 Suppl:A101.
14. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. American Journal of Respiratory and Critical Care Medicine 2003;167(4):512-20. [PUBMED: 12426230]
15. Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua Nei Ke Za Zhi 2012;51:599-603.
16. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases 1988;138(1):62-8. [PUBMED: 3202402]
17. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednislone infusion in early ARDS: result of a randomised controlled trial. Chest 2007;131(4):954-63. [PUBMED: 17426195]
18. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. The Lancet 2011;377:2023-30.
19. Oppert M, Schindler R, Husung C, Offerman K, Graef KJ, Boenisch O, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine 2005;33:2457-64. [PUBMED: 16276166]
20. Rezk NA, Ibrahim AM. Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis 2013;62(1):167-72.
21. Rinaldi S, Adembri C, Grechi S, DE Gaudio R. Low-dose hydrocortisone during severe sepsis: effects on microalbumineria. Critical Care Medicine 2006;34:2334-9. [PUBMED: 16850006]
22. Sabry NA, El-Din Omar E. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacology and Pharmacy 2011;2:73-81.
23. Schumer W. Steroids in the treatment of clinical septic shock. Annals of Surgery 1976;184(3):333-41. [PUBMED: 786190]
24. Slusher T, Gbadero D, Howard C, Lewinson L, Giroir B, Toro L, et al. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal 1996;15(7):579-83. [PUBMED: 8823850]
25. Snijders D, Daniels JMA, de GraaffCS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia - a randomized double blinded clinical trial. American Journal of Respiratory and Critical Care Medicine 2010;181:975-82.
26. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine 1984;311(18):1137-43. [PUBMED: 6384785]
27. Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock. New England Journal of Medicine 2008;358:111-24. [PUBMED: 18184957]
28. Tandan SM, Guleria R, Gupta N. Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Proceedings of the American Thoracic Society Meeting. 2005:A24.
29. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; Vol. 313:677-86.
30. Valoor HT, Singhi S, Jayashree M. Low-dose hydrocortisone in paediatric septic shock: an exploratory study in a third world setting. Pediatric Critical Care Medicine 2009;10:121-5.
31. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine 1987;317(11):659-65. [PUBMED: 2888017]
32. Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiologic-dose steroid therapy in sepsis. Critical Care 2002;6(3):251-9. [PUBMED: 12133187]
33. Yildiz O, Tanriverdi F, Simsek S, Aygen B, Kelestimur F. The effects of moderate-dose steroid therapy in sepsis: a placebo-controlled, randomized study. Journal of Research in Medical Sciences 2011;16:1410-21.
34. Cicarelli DD, Bensenor FEM, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Medical Journal 2006;124:90-5. [PUBMED: 16878192]
35. Hahn EO, Houser HB, Rammelkamp CH, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. Journal of Clinical Investigation 1951;30:274-81.
36. Hughes GS Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sciences 1984;35(23):2319-26. [PUBMED: 6390057]
37. Kaufmann I, Briegel J, Schliephake F, Hoelzl A, Chouker A, Hummel T, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Medicine 2008;34:344-9. [PUBMED: 17906853]
38. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. New England Journal of Medicine 1971;284(22):1248-50. [PUBMED: 4929896]
39. Lucas C, Ledgerwood A. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Archives of Surgery 1984;119(5):537-41. [PUBMED: 6712466]
40. McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983;1(8322):484. [PUBMED: 6131207]
41. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280(2):159-65. [PUBMED: 9669790]
42. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55. [PUBMED: 17710485]
43. Rogers J. Large doses of steroids in septicaemic shock. British Journal of Urology 1970;42(6):742. [PUBMED: 4923652]
44. Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kvols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study). Clinical Research 1976;24:258A.
45. Venet F, Plassais J, Textoris J, Cazalis MA, Pachot A, Bertin-Maghit M, et al. Low-dose hydrocortisone reduces norepinephrine duration in severe burn patients: a randomized clinical trial. Critical Care 2015;19:21.
46. Wagner HN, Bennett IL, Lasagna L, CluffLE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bulletin of Johns Hopkins Hospital 1955;98:197-215. [PUBMED: 13304518]
47. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Archives of Surgery 1985;120(5):536-40. [PUBMED: 3885915]
48. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015;385:1511-8.
49. Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ. Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). British Medical Journal Open 2014;4:e005866.
50. 6-Methylprednisolone for multiple organ dysfunction syndrome. Ongoing study 01/08/2005.
51. Hydrocortisone versus hydrocortisone plus fludrocortisone for treatment of adrenal insufficiency in sepsis. Ongoing study September 2006.
52. Steroids in patients with early ARDS. Ongoing study February 2008.
53. Activated protein C and corticosteroids for human septic shock (APROCCHS). Ongoing study April 2008.
54. Hydrocortisone for prevention of septic shock. Ongoing study 01/06/2008.
55. Evaluation of corticosteroid therapy in childhood severe sepsis: a randomized pilot study. Ongoing study 01/04/2008.
56. Venkatesh B, Myburgh J, Finfer S, Webb SA, Cohen J, Bellomo R, et al. ANZICS CTG Investigtors. The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Critical Care resuscitation 2013;15:83-8.
57. ACCP/SCCM Consensus Conference Panel. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20(6):864-74. [PUBMED: 1597042]
58. Angus DC, van der Poll T. Severe sepsis and septic shock. New England Journal of Medicine 2013;369:840-51.
59. Annane D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283(8):1038-45. [PUBMED: 10697064]
60. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Rea Network. Current epidemiology of septic shock: the CUB-Réa Network. American Journal of Respiratory and Critical Care Medicine 2003;168(2):165-72. [PUBMED: 12851245]
61. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78. [PUBMED: 15639681]
62. Annane D. Improving clinical trials in the critically ill: unique challenge: sepsis. Critical Care Medicine 2009;37 Suppl:117-28. [PUBMED: 19104211]
63. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, et al. on behalf of the APROCCHSS Trial Investigators. Recombinant human activated protein C for adults with septic shock: a randomised controlled trial. American Journal of Respiratory and Critical Care Medicine 2013;187:1091-7.
64. Barczyk K, Ehrchen J, Tenbrock K, Ahlmann M, Kneidl J, Viemann D, et al. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3. Blood 2010;116:446-55.
65. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. American Journal of Respiratory and Critical Care Medicine 1995;152 Suppl(6 Pt 2):125-40. [PUBMED: 7489120]
66. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Annals of Internal Medicine 1991;114(4):332-3. [PUBMED: 1987879]
67. Boonen E, Vervenne H, Meersseman P, Andrew R, Mortier L, Declercq PE, et al. Reduced cortisol metabolism during critical illness. New England Journal of Medicine 2013;388:1477-88.
68. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clinical Investigation 1994;72:782-7. [PUBMED: 7865982]
69. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. Journal of Clinical Investigation 2008;118:364-75.
70. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine 1995;322(20):1351-62. [PUBMED: 7715646]
71. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. New England Journal of Medicine 2003;348(8):727-34. [PUBMED: 12594318]
72. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MAD, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Critical Care Medicine 1995;23(8):1430-9. [PUBMED: 7634816]
73. de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. Journal of Immunology 2007;178:1845-51. [PUBMED: 17237435]
74. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008;36:296-327. [PUBMED: 20035219]
75. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive care Medicine 2013;39:165-228.
76. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-3. [PUBMED: 11308438]
77. Villa Bianca RE, Lippolis L, Autore G, Popolo A, Marzocco S, Sorrentino L, et al. Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channel activity. British Journal of Pharmacology 2003;140:91-6.
78. Duma D, Silva-Santos JE, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Critical Care Medicine 2004;32:2304-10.
79. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [PUBMED: 9310563]
80. Ehrchen J, Steinmüller L, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007;109:1265-74.
81. Fabian TC, Patterson R. Steroid therapy in septic shock. Survival studies in a laboratory model. American Surgeon 1982;48(12):614-7. [PUBMED: 6760756]
82. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Medicine 2004;30:589-96. [PUBMED: 14963646]
83. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of glucocorticoid receptor binding by nitric oxide. Molecular Pharmacology 1999;55:317-23.
84. Goodwin JE, Feng Y, Velazquez H, Sessa WC. Endothelial glucocorticoid receptor is required for protection against sepsis. Proceeding of the National Academy of Science 2013;110:306-11.
85. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. [PUBMED: 18436948]
86. Guyatt GH, Wyer P, Ioannidis J. When to believe a subgroup analysis. In: Guyatt G, Rennie R, Meade M, Cook D editor(s). User's Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York: McGraw-Hill, 2008.
87. Heller AR, Heller SC, Borkenstein A, Stehr SN, Koch T. Modulation of host defense by hydrocortisone in stress doses during endotoxaemia. Intensive Care Medicine 2003;29:1456-63. [PUBMED: 12879235
88. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
89. Hotta M, Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proceedings of the National Academy of Sciences of the United States of America 1986;83(20):7795-9. [PUBMED: 3020557]
90. Huang ZH, Gao H, Xu RB. Study on glucocorticoid receptors during intestinal ischemia shock and septic shock. Circulatory Shock 1987;23(1):27-36. [PUBMED: 3690811]
91. Ioannidis JPA. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141:781-8.
92. Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128(1):623-9. [PUBMED: 1702707]
93. Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Medicine 2011;37:420-9.
94. Kanczkowski W, Alexaki VI, Tran N, Großklaus S, Zacharowski K, Martinez A, et al. Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proceedings of the National Academy of Science 2013;110:14801-6.
95. Katsenos CS, Antonopoulou AN, Apostolidou EN, Ioakeimidou A, Kalpakou GT, Papanikolaou MN, et al. on behalf of the Hellenic Sepsis Study Group. Early administration of hydrocortisone replacement after the advent of septic shock: impact on survival and immune response. Critical Care Medicine 2014;42:1651-7.
96. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of Internal Medicine 2007;168:1468-9. [PUBMED: 17698689]
97. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Critical Care Medicine 1995;23(7):1294-303. [PUBMED: 7600840]
98. Lipiner D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, et al. Adrenal function in sepsis: the retrospective CORTICUS cohort study. Critical Care Medicine 2007;35:1012-8.
99. Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Critical Care 2007;11:R21. [PUBMED: 17306016]
100. Lowenberg M, Tuynman J, Bilderbeek J, Gaber T, Buttgereit F, van Deventer S, et al. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 2005;106:1703-10.
101. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Critical Care Medicine 2008;36:1937-49.
102. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine 2003;348:1546-54. [PUBMED: 12700374]
103. Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way?. Chest 1998;114(2):355-60. [PUBMED: 9726712]
104. Melby JC, Spink WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. Journal of Clinical Investigation 1958;37:1791-8.
105. Menon K, McNally D, Choong K, Sampson M. A systematic review and meta-analysis on the effect of steroids in pediatric shock. Pediatric Critical Care Medicine 2013;14:474-80.
106. Molijn GJ, Koper JW, van Uffelen CJ, de Jong FH, Brinkmann AO, Bruining HA, et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clinical Endocrinology 1995;43(2):197-203. [PUBMED: 7554315]
107. Moran JL, Graham PL, RockliffS, Bersten AD. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. Critical Care 2010;14:R134.
108. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors, and a conformational ensemble model. Nature Revue Drug Discovery 2004;3:27-41.
109. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Critical Care Medicine 2003;31:2332-8. [PUBMED: 14501964]
110. Park HY, Suh GY, Song JU, Yoo H, Jo IJ, Shin TG, et al. Early initiation of low-dose corticosteroid therapy in the management of septic shock: a retrospective observational study. Critical Care 2012;16:R3.
111. Parrillo JE. Pathogenic mechanisms of septic shock. New England Journal of Medicine 1993;328(20):1471-7.
112. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61:991-6.
113. Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V, et al. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One 2011;6:e25905.
114. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
115. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. New England Journal of Medicine 2005;353:1711-23.
116. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337(8741):582-3.
117. Sharshar T1, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E, Dorandeu A, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. The Lancet 2003;362:1799-805.
118. Sherwin RL, Garcia AJ, Bilkovski R. Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review and position statement prepared for the American Academy of Emergency Medicine. Journal of Emergency Medicine 2012;43:7-12.
119. Singer M, Deutschman CS, Seymour CW, Shankar Hari M, Angus DC, Annane D, et al. The Sepsis Definitions Task Force. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Journal of American Medical Association 2015:in press.
120. The EPISPESIS Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Medicine 2004;30:580-8. [PUBMED: 14997295]
121. Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, et al. Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock 2004;21::484-91.
122. Vachharajani V, Vital S, Russell J, Scott LK, Granger DN. Glucocorticoids inhibit the cerebral microvascular dysfunction associated with sepsis in obese mice. Microcirculation 2006;13:477-87. [PUBMED: 16864414]
123. Varga G, Ehrchen J, Tsianakas A, Tenbrock K, Rattenholl A, Seeliger S, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. Journal of Leukocyte Biology 2008;84:644-50.
124. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Medicine 1996;22:707-10.
125. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013;381:774-5.
126. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD002243.pub2]
127. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75. [PUBMED: 19509383]